The UK’s reimbursement agency has recommended the use of Novartis’ (NOVN: VX) Zolgensma (onasemnogene abeparvovec) for spinal muscular atrophy (SMA) in babies.
The National Institute for Health and Care Excellence (NICE) has agreed a discount scheme with the Swiss drugmaker to unlock access for patients.
The agreement covers babies under the age of six months, or aged seven to 12 months, if their treatment is agreed by a national multidisciplinary team.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze